When trial results come in for a company in the health care space, it's often do or die, make or break. In this video, Motley Fool health care analyst David Williamson takes us through three such results just in, and what's happened with shares as a result. Tranzyme (NASDAQ:TZYM) was today's biggest loser, with shares down a devastating 75% after results came in that its drug TZP-102 was no better than a placebo in helping gastroparesis patients. AcelRX (NASDAQ:ACRX), on the other hand, was up after excellent results with its drug sufentanil nanotab pca in comparison with intravenous morphine for treating post-operative pain, and Threshold Pharmaceuticals (NASDAQ:THLD) experienced a jump up that has now settled back down, after some initial excitement about the results of its drug TH302 applied to maintenance therapy for soft-tissue sarcoma.
Motley Fool Returns
Discounted offers are only available to new members. Stock Advisor will renew at the then current list price. Stock Advisor list price is $199 per year.
Stock Advisor launched in February of 2002. Returns as of 10/22/2021.
Average returns of all recommendations since inception. Cost basis and return based on previous market day close.